Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer.

Carter R, Cheraghchi-Bashi A, Westhorpe A, Yu S, Shanneik Y, Seraia E, Ouaret D, Inoue Y, Koch C, Wilding J, Ebner D, Ryan AJ, Buffa FM, Sharma RA.

Cancer Biol Med. 2019 May;16(2):234-246. doi: 10.20892/j.issn.2095-3941.2018.0284.

2.

E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition.

Burdova K, Yang H, Faedda R, Hume S, Chauhan J, Ebner D, Kessler BM, Vendrell I, Drewry DH, Wells CI, Hatch SB, Dianov GL, Buffa FM, D'Angiolella V.

EMBO J. 2019 Oct 15;38(20):e101443. doi: 10.15252/embj.2018101443. Epub 2019 Aug 19.

3.

MITF controls the TCA cycle to modulate the melanoma hypoxia response.

Louphrasitthiphol P, Ledaki I, Chauhan J, Falletta P, Siddaway R, Buffa FM, Mole DR, Soga T, Goding CR.

Pigment Cell Melanoma Res. 2019 Nov;32(6):792-808. doi: 10.1111/pcmr.12802. Epub 2019 Jul 8.

PMID:
31207090
4.

Science in Focus: Bioinformatics Part 1 - Lost in Translation.

O'Cathail SM, Buffa FM.

Clin Oncol (R Coll Radiol). 2019 Jun;31(6):337-340. doi: 10.1016/j.clon.2019.03.043. Epub 2019 Apr 8. No abstract available.

PMID:
30975523
5.

Guidelines for using sigQC for systematic evaluation of gene signatures.

Dhawan A, Barberis A, Cheng WC, Domingo E, West C, Maughan T, Scott JG, Harris AL, Buffa FM.

Nat Protoc. 2019 May;14(5):1377-1400. doi: 10.1038/s41596-019-0136-8. Epub 2019 Apr 10.

PMID:
30971781
6.

Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism.

Valli A, Morotti M, Zois CE, Albers PK, Soga T, Feldinger K, Fischer R, Frejno M, McIntyre A, Bridges E, Haider S, Buffa FM, Baban D, Rodriguez M, Yanes O, Whittington HJ, Lake HA, Zervou S, Lygate CA, Kessler BM, Harris AL.

Mol Cancer Res. 2019 Jul;17(7):1531-1544. doi: 10.1158/1541-7786.MCR-18-0315. Epub 2019 Mar 18.

PMID:
30885992
7.

Modeling genotypes in their microenvironment to predict single- and multi-cellular behavior.

Voukantsis D, Kahn K, Hadley M, Wilson R, Buffa FM.

Gigascience. 2019 Mar 1;8(3). pii: giz010. doi: 10.1093/gigascience/giz010.

8.

Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors.

Dhawan A, Scott JG, Harris AL, Buffa FM.

Nat Commun. 2018 Dec 7;9(1):5228. doi: 10.1038/s41467-018-07657-1.

9.

The many faces of mathematical modelling in oncology.

Victori P, Buffa FM.

Br J Radiol. 2019 Jan;92(1093):20180856. doi: 10.1259/bjr.20180856. Epub 2018 Nov 28. Review.

PMID:
30485129
10.

Endogenous miRNA sponges mediate the generation of oscillatory dynamics for a non-coding RNA network.

Dhawan A, Harris AL, Buffa FM, Scott JG.

J Theor Biol. 2019 Nov 21;481:54-60. doi: 10.1016/j.jtbi.2018.10.055. Epub 2018 Oct 30.

PMID:
30385313
11.

Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer.

Lord SR, Cheng WC, Liu D, Gaude E, Haider S, Metcalf T, Patel N, Teoh EJ, Gleeson F, Bradley K, Wigfield S, Zois C, McGowan DR, Ah-See ML, Thompson AM, Sharma A, Bidaut L, Pollak M, Roy PG, Karpe F, James T, English R, Adams RF, Campo L, Ayers L, Snell C, Roxanis I, Frezza C, Fenwick JD, Buffa FM, Harris AL.

Cell Metab. 2018 Nov 6;28(5):679-688.e4. doi: 10.1016/j.cmet.2018.08.021. Epub 2018 Sep 20.

12.

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.

Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML.

EBioMedicine. 2018 May;31:182-189. doi: 10.1016/j.ebiom.2018.04.019. Epub 2018 Apr 23.

13.

Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project.

Robbe P, Popitsch N, Knight SJL, Antoniou P, Becq J, He M, Kanapin A, Samsonova A, Vavoulis DV, Ross MT, Kingsbury Z, Cabes M, Ramos SDC, Page S, Dreau H, Ridout K, Jones LJ, Tuff-Lacey A, Henderson S, Mason J, Buffa FM, Verrill C, Maldonado-Perez D, Roxanis I, Collantes E, Browning L, Dhar S, Damato S, Davies S, Caulfield M, Bentley DR, Taylor JC, Turnbull C, Schuh A; 100,000 Genomes Project.

Genet Med. 2018 Oct;20(10):1196-1205. doi: 10.1038/gim.2017.241. Epub 2018 Feb 1.

14.

miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense.

Pajic M, Froio D, Daly S, Doculara L, Millar E, Graham PH, Drury A, Steinmann A, de Bock CE, Boulghourjian A, Zaratzian A, Carroll S, Toohey J, O'Toole SA, Harris AL, Buffa FM, Gee HE, Hollway GE, Molloy TJ.

Cancer Res. 2018 Jan 15;78(2):501-515. doi: 10.1158/0008-5472.CAN-16-3105. Epub 2017 Nov 27.

15.

IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer.

Aleksic T, Verrill C, Bryant RJ, Han C, Worrall AR, Brureau L, Larré S, Higgins GS, Fazal F, Sabbagh A, Haider S, Buffa FM, Cole D, Macaulay VM.

Br J Cancer. 2017 Nov 21;117(11):1600-1606. doi: 10.1038/bjc.2017.337. Epub 2017 Oct 3.

16.

Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer.

D'Costa Z, Jones K, Azad A, van Stiphout R, Lim SY, Gomes AL, Kinchesh P, Smart SC, Gillies McKenna W, Buffa FM, Sansom OJ, Muschel RJ, O'Neill E, Fokas E.

Cancer Res. 2017 Nov 1;77(21):5952-5962. doi: 10.1158/0008-5472.CAN-16-2833. Epub 2017 Aug 1.

17.

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.

Pirovano G, Ashton TM, Herbert KJ, Bryant RJ, Verrill CL, Cerundolo L, Buffa FM, Prevo R, Harrap I, Ryan AJ, Macaulay V, McKenna WG, Higgins GS.

Br J Cancer. 2017 Aug 8;117(4):503-512. doi: 10.1038/bjc.2017.197. Epub 2017 Jul 4.

18.

In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer.

Abu-Jamous B, Buffa FM, Harris AL, Nandi AK.

Mol Cancer. 2017 Jun 15;16(1):105. doi: 10.1186/s12943-017-0673-0.

19.

Depletion of signal recognition particle 72kDa increases radiosensitivity.

Prevo R, Tiwana GS, Maughan TS, Buffa FM, McKenna WG, Higgins GS.

Cancer Biol Ther. 2017 Jun 3;18(6):425-432. doi: 10.1080/15384047.2017.1323587. Epub 2017 May 11.

20.

A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.

Yang L, Taylor J, Eustace A, Irlam JJ, Denley H, Hoskin PJ, Alsner J, Buffa FM, Harris AL, Choudhury A, West CML.

Clin Cancer Res. 2017 Aug 15;23(16):4761-4768. doi: 10.1158/1078-0432.CCR-17-0038. Epub 2017 Apr 11.

21.

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.

Falletta P, Sanchez-Del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, Siddaway R, Lisle R, Freter R, Daniels MJ, Lu X, Tüting T, Middleton M, Buffa FM, Willis AE, Pavitt G, Ronai ZA, Sauka-Spengler T, Hölzel M, Goding CR.

Genes Dev. 2017 Jan 1;31(1):18-33. doi: 10.1101/gad.290940.116. Epub 2017 Jan 17.

22.

Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D.

Gascoyne DM, Lyne L, Spearman H, Buffa FM, Soilleux EJ, Banham AH.

Endocrinology. 2017 Mar 1;158(3):503-515. doi: 10.1210/en.2016-1802.

23.

Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells.

Timosenko E, Ghadbane H, Silk JD, Shepherd D, Gileadi U, Howson LJ, Laynes R, Zhao Q, Strausberg RL, Olsen LR, Taylor S, Buffa FM, Boyd R, Cerundolo V.

Cancer Res. 2016 Nov 1;76(21):6193-6204. Epub 2016 Sep 20.

24.

Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.

Mehta S, Hughes NP, Li S, Jubb A, Adams R, Lord S, Koumakis L, van Stiphout R, Padhani A, Makris A, Buffa FM, Harris AL.

EBioMedicine. 2016 Aug;10:109-16. doi: 10.1016/j.ebiom.2016.07.017. Epub 2016 Jul 16.

25.

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.

Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, Kelly CJ, Pirovano G, Buffa FM, Hammond EM, Stratford M, Muschel RJ, Higgins GS, McKenna WG.

Nat Commun. 2016 Jul 25;7:12308. doi: 10.1038/ncomms12308.

26.

Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia.

Haider S, McIntyre A, van Stiphout RG, Winchester LM, Wigfield S, Harris AL, Buffa FM.

Genome Biol. 2016 Jun 29;17(1):140. doi: 10.1186/s13059-016-0999-8.

27.

FANCD2 limits replication stress and genome instability in cells lacking BRCA2.

Michl J, Zimmer J, Buffa FM, McDermott U, Tarsounas M.

Nat Struct Mol Biol. 2016 Aug;23(8):755-757. doi: 10.1038/nsmb.3252. Epub 2016 Jun 20.

28.

SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development.

Raducu M, Fung E, Serres S, Infante P, Barberis A, Fischer R, Bristow C, Thézénas ML, Finta C, Christianson JC, Buffa FM, Kessler BM, Sibson NR, Di Marcotullio L, Toftgård R, D'Angiolella V.

EMBO J. 2016 Jul 1;35(13):1400-16. doi: 10.15252/embj.201593374. Epub 2016 May 27.

29.

Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.

Frago S, Nicholls RD, Strickland M, Hughes J, Williams C, Garner L, Surakhy M, Maclean R, Rezgui D, Prince SN, Zaccheo OJ, Ebner D, Sanegre S, Yu S, Buffa FM, Crump MP, Hassan AB.

Proc Natl Acad Sci U S A. 2016 May 17;113(20):E2766-75. doi: 10.1073/pnas.1513023113. Epub 2016 May 2.

30.

Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer.

Yang J, AlTahan A, Jones DT, Buffa FM, Bridges E, Interiano RB, Qu C, Vogt N, Li JL, Baban D, Ragoussis J, Nicholson R, Davidoff AM, Harris AL.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15172-7. doi: 10.1073/pnas.1422015112. Epub 2015 Nov 23.

31.

MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer.

Gee HE, Buffa FM, Harris AL, Toohey JM, Carroll SL, Cooper CL, Beith J, McNeil C, Carmalt H, Mak C, Warrier S, Holliday A, Selinger C, Beckers R, Kennedy C, Graham P, Swarbrick A, Millar EK, O'Toole SA, Molloy T.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1104-14. doi: 10.1016/j.ijrobp.2015.08.046. Epub 2015 Sep 3.

PMID:
26581147
32.

Gene Expression Signatures as Biomarkers of Tumour Hypoxia.

Harris BH, Barberis A, West CM, Buffa FM.

Clin Oncol (R Coll Radiol). 2015 Oct;27(10):547-60. doi: 10.1016/j.clon.2015.07.004. Epub 2015 Aug 14. Review.

PMID:
26282471
33.

Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT.

Leszczynska KB, Foskolou IP, Abraham AG, Anbalagan S, Tellier C, Haider S, Span PN, O'Neill EE, Buffa FM, Hammond EM.

J Clin Invest. 2015 Jun;125(6):2385-98. doi: 10.1172/JCI80402. Epub 2015 May 11.

34.

RIPOSTE: a framework for improving the design and analysis of laboratory-based research.

Masca NG, Hensor EM, Cornelius VR, Buffa FM, Marriott HM, Eales JM, Messenger MP, Anderson AE, Boot C, Bunce C, Goldin RD, Harris J, Hinchliffe RF, Junaid H, Kingston S, Martin-Ruiz C, Nelson CP, Peacock J, Seed PT, Shinkins B, Staples KJ, Toombs J, Wright AK, Teare MD.

Elife. 2015 May 7;4. doi: 10.7554/eLife.05519.

35.

Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen.

Tiwana GS, Prevo R, Buffa FM, Yu S, Ebner DV, Howarth A, Folkes LK, Budwal B, Chu KY, Durrant L, Muschel RJ, McKenna WG, Higgins GS.

Oncotarget. 2015 Mar 20;6(8):5978-89.

36.

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.

Leung WY, Roxanis I, Sheldon H, Buffa FM, Li JL, Harris AL, Kong A.

Oncotarget. 2015 Mar 20;6(8):5678-94.

37.

Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.

van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MHW, Yao CQ, Ivan M, Ivan C, Pecot CV, Boutros PC, Sood AK, Koritzinsky M, Wouters BG.

Nat Commun. 2014 Oct 29;5:5203. doi: 10.1038/ncomms6203.

38.

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D.

J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. Review.

PMID:
25347767
39.

Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation.

Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S, Buffa FM, Li JL, Zhang Q, Wakelam MJO, Karpe F, Schulze A, Harris AL.

Cell Rep. 2014 Oct 9;9(1):349-365. doi: 10.1016/j.celrep.2014.08.056. Epub 2014 Sep 25.

40.

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.

Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB.

Br J Cancer. 2014 Jul 8;111(1):46-54. doi: 10.1038/bjc.2014.236. Epub 2014 May 29.

41.

Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia.

Camps C, Saini HK, Mole DR, Choudhry H, Reczko M, Guerra-Assunção JA, Tian YM, Buffa FM, Harris AL, Hatzigeorgiou AG, Enright AJ, Ragoussis J.

Mol Cancer. 2014 Feb 11;13:28. doi: 10.1186/1476-4598-13-28.

42.

Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression.

Airley RE, McHugh P, Evans AR, Harris B, Winchester L, Buffa FM, Al-Tameemi W, Leek R, Harris AL.

Br J Cancer. 2014 Feb 4;110(3):715-23. doi: 10.1038/bjc.2013.765. Epub 2013 Dec 24.

43.

A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.

Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM.

Cancer Cell. 2013 Aug 12;24(2):229-41. doi: 10.1016/j.ccr.2013.06.004. Epub 2013 Jul 18.

44.

A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.

Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts GN, Denley H, Miller CJ, Homer JJ, Rojas AM, Hoskin PJ, Buffa FM, Harris AL, Kaanders JH, West CM.

Clin Cancer Res. 2013 Sep 1;19(17):4879-88. doi: 10.1158/1078-0432.CCR-13-0542. Epub 2013 Jul 2.

45.

Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer.

Blick C, Ramachandran A, Wigfield S, McCormick R, Jubb A, Buffa FM, Turley H, Knowles MA, Cranston D, Catto J, Harris AL.

Br J Cancer. 2013 Jul 9;109(1):50-9. doi: 10.1038/bjc.2013.240. Epub 2013 Jun 18.

46.

Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells.

Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C, Steers G, Turley H, Li JL, Günther UL, Buffa FM, McIntyre A, Harris AL.

Cell Metab. 2012 Dec 5;16(6):751-64. doi: 10.1016/j.cmet.2012.10.017. Epub 2012 Nov 21.

47.

Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma.

Betts GN, Eustace A, Patiar S, Valentine HR, Irlam J, Ramachandran A, Merve A, Homer JJ, Möller-Levet C, Buffa FM, Hall G, Miller CJ, Harris AL, West CM.

Eur J Cancer. 2013 Jan;49(1):156-65. doi: 10.1016/j.ejca.2012.07.028. Epub 2012 Aug 27.

PMID:
22951015
48.

p-Medicine: From data sharing and integration via VPH models to personalized medicine.

Rossi S, Christ-Neumann M, Rüping S, Buffa F, Wegener D, McVie G, Coveney P, Graf N, Delorenzi M.

Ecancermedicalscience. 2011;5:218. doi: 10.3332/ecancer.2011.218. Epub 2011 Aug 17.

49.

Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression.

Yang J, Staples O, Thomas LW, Briston T, Robson M, Poon E, Simões ML, El-Emir E, Buffa FM, Ahmed A, Annear NP, Shukla D, Pedley BR, Maxwell PH, Harris AL, Ashcroft M.

J Clin Invest. 2012 Feb;122(2):600-11. doi: 10.1172/JCI58780. Epub 2012 Jan 3.

50.

Igf2 ligand dependency of Pten(+/-) developmental and tumour phenotypes in the mouse.

Church DN, Phillips BR, Stuckey DJ, Barnes DJ, Buffa FM, Manek S, Clarke K, Harris AL, Carter EJ, Hassan AB.

Oncogene. 2012 Aug 2;31(31):3635-46. doi: 10.1038/onc.2011.526. Epub 2011 Nov 28.

Supplemental Content

Loading ...
Support Center